{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:11:37Z","timestamp":1792174297936,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA102667"],"award-info":[{"award-number":["CA102667"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI141531"],"award-info":[{"award-number":["AI141531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI098511"],"award-info":[{"award-number":["AI098511"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43 153707"],"award-info":[{"award-number":["D43 153707"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Interferon (IFN)- \u03bb4, a type III IFN, production is controlled by a dinucleotide frameshift variant (rs368234815-dG\/TT) within the first exon of the\n                      <jats:italic>IFNL4<\/jats:italic>\n                      gene. Carriers of the\n                      <jats:italic>IFNL4<\/jats:italic>\n                      -dG allele but not the\n                      <jats:italic>IFNL4<\/jats:italic>\n                      -TT allele are able to produce the IFN-\u03bb4 protein. Patients with hepatitis C virus that do not produce the IFN-\u03bb4 protein have higher rates of viral clearance suggesting a potential inhibitory role of IFN-\u03bb4 in liver-tropic infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, it was investigated whether children infected with\n                      <jats:italic>Plasmodium falciparum,<\/jats:italic>\n                      which has a well-characterized liver stage infection, would be more susceptible to clinical malaria relative to their\n                      <jats:italic>IFNL4<\/jats:italic>\n                      -rs368234815 allele. A cohort of 122 children from a malaria holoendemic region of Kenya was analysed. Episodes of clinical malaria and upper respiratory tract infections (URTIs) were determined using information collected from birth to 2\u00a0years of age. The dinucleotide frameshift variant\n                      <jats:italic>IFNL4<\/jats:italic>\n                      -rs368234815-dG\/TT was genotyped using a TaqMan assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this cohort, 33% of the study participants had the dG\/dG genotype, 45% had the dG\/TT genotype, and 22% had TT\/TT genotype. The number and time to first episode of clinical malaria and URTIs with respect to the\n                      <jats:italic>IFNL4<\/jats:italic>\n                      -rs368234815 allele was evaluated. It was found that children that carried the\n                      <jats:italic>IFNL4-<\/jats:italic>\n                      rs368234815-dG allele had an increased number of clinical malaria episodes. In addition, there was a significant association between earlier age of first malaria infection with carriers of the\n                      <jats:italic>IFNL4<\/jats:italic>\n                      -dG allele (\n                      <jats:italic>p-value:<\/jats:italic>\n                      0.021).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The results suggest that the ability to produce IFN-\u03bb4 negatively affects host immune protection against\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      malaria in Kenyan children.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-03689-z","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:12:04Z","timestamp":1618981924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["IFN-\u03bb4 genetic variants influence clinical malaria episodes in a cohort of Kenyan children"],"prefix":"10.1186","volume":"20","author":[{"given":"Gabriela","family":"Samayoa-Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conner","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Ogolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sabourin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeola","family":"Obajemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene E.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmilla","family":"Prokunina-Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-5152","authenticated-orcid":false,"given":"Rosemary","family":"Rochford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"3689_CR1","first-page":"2020","volume-title":"20 years of global progress and challenges","author":"WHO. World malaria report","year":"2020","unstructured":"WHO. World malaria report. 20 years of global progress and challenges. Geneva: World Health Organization; 2020. p. 2020."},{"key":"3689_CR2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ni.3212","volume":"16","author":"A Wack","year":"2015","unstructured":"Wack A, Terczy\u0144ska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015;16:802\u20139.","journal-title":"Nat Immunol"},{"key":"3689_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","volume":"43","author":"HM Lazear","year":"2015","unstructured":"Lazear HM, Nice TJ, Diamond MS. Interferon-\u03bb: immune functions at barrier surfaces and beyond. Immunity. 2015;43:15\u201328.","journal-title":"Immunity"},{"key":"3689_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164\u201371.","journal-title":"Nat Genet"},{"key":"3689_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/jir.2019.0043","volume":"39","author":"L Prokunina-Olsson","year":"2019","unstructured":"Prokunina-Olsson L. Genetics of the human interferon lambda region. J Interferon Cytokine Res. 2019;39:599\u2013608.","journal-title":"J Interferon Cytokine Res"},{"key":"3689_CR6","doi-asserted-by":"publisher","first-page":"e1004681","DOI":"10.1371\/journal.pgen.1004681","volume":"10","author":"FM Key","year":"2014","unstructured":"Key FM, Peter B, Dennis MY, Huerta-S\u00e1nchez E, Tang W, Prokunina-Olsson L, et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet. 2014;10:e1004681.","journal-title":"PLoS Genet"},{"key":"3689_CR7","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/infdis\/jit827","volume":"209","author":"EG Meissner","year":"2014","unstructured":"Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O\u2019Brien TR, et al. IFNL4-\u0394G Genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209:1700\u20134.","journal-title":"J Infect Dis"},{"key":"3689_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/infdis\/jit433","volume":"209","author":"PV Aka","year":"2014","unstructured":"Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-\u0394G allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis. 2014;209:350\u20134.","journal-title":"J Infect Dis"},{"key":"3689_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jhep.2015.06.035","volume":"63","author":"TR O\u2019Brien","year":"2015","unstructured":"O\u2019Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015;63:1103\u201310.","journal-title":"J Hepatol"},{"key":"3689_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1089\/jir.2019.0044","volume":"39","author":"OO Onabajo","year":"2019","unstructured":"Onabajo OO, Muchmore B, Prokunina-Olsson L. The IFN-\u03bb4 conundrum: when a good interferon goes bad. J Interferon Cytokine Res. 2019;39:636\u201341.","journal-title":"J Interferon Cytokine Res"},{"key":"3689_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fcimb.2019.00340","volume":"9","author":"B Rugwizangoga","year":"2019","unstructured":"Rugwizangoga B, Andersson ME, Kabayiza J-C, Nilsson MS, \u00c1rmannsd\u00f3ttir B, Aurelius J, et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect Microbiol. 2019;9:340.","journal-title":"Front Cell Infect Microbiol"},{"key":"3689_CR12","doi-asserted-by":"publisher","first-page":"ofz237","DOI":"10.1093\/ofid\/ofz237","volume":"6","author":"JE Ray","year":"2019","unstructured":"Ray JE, Dobbs KR, Ogolla SO, Daud II, Vulule J, Sumba PO, et al. Reduced transplacental transfer of antimalarial antibodies in Kenyan HIV-exposed uninfected infants. Open Forum Infect Dis. 2019;6:ofz237.","journal-title":"Open Forum Infect Dis."},{"key":"3689_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s10995-014-1546-4","volume":"19","author":"II Daud","year":"2015","unstructured":"Daud II, Ogolla S, Amolo AS, Namuyenga E, Simbiri K, Bukusi EA, et al. Plasmodium falciparum infection is associated with Epstein-Barr virus reactivation in pregnant women living in malaria holoendemic area of Western Kenya. Matern Child Health J. 2015;19:606\u201314.","journal-title":"Matern Child Health J"},{"key":"3689_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1046\/j.1365-2141.1999.01230.x","volume":"104","author":"R Kotea","year":"1999","unstructured":"Kotea R, Kaeda JS, Yan SLK, Sem Fa N, Beesoon S, Jankee S, et al. Three major G6PD-deficient polymorphic variants identified among the Mauritian population. Br J Haematol. 1999;104:849\u201354.","journal-title":"Br J Haematol"},{"key":"3689_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ijc.28378","volume":"134","author":"DH Mulama","year":"2014","unstructured":"Mulama DH, Bailey JA, Foley J, Chelimo K, Ouma C, Jura WGZO, et al. Sickle cell trait is not associated with endemic Burkitt lymphoma: an ethnicity and malaria endemicity-matched case-control study suggests factors controlling EBV may serve as a predictive biomarker for this pediatric cancer: sickle cell trait and EBV loads in endemic Burkitt lymphoma. Int J Cancer. 2014;134:645\u201353.","journal-title":"Int J Cancer"},{"key":"3689_CR16","unstructured":"Therneau T. A Package for Survival Analysis in S. version 2.38. 2015. https:\/\/CRAN.R-project.org\/package=survival."},{"key":"3689_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival sata: extending the Cox model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling survival sata: extending the Cox model. New York.: Springer; 2000."},{"key":"3689_CR18","unstructured":"Kassambara A, Kosinski M, Biecek P. survminer: drawing survival curves using \u201cggplot2\u201d. R package version 0.4.6. 2019. https:\/\/CRAN.R-project.org\/package=survminer."},{"key":"3689_CR19","unstructured":"Rich B. table1: Tables of Descriptive Statistics in HTML. R package version 1.2.1. 2020. https:\/\/CRAN.R-project.org\/package=table1."},{"key":"3689_CR20","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2020. https:\/\/www.R-project.org\/."},{"key":"3689_CR21","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1371\/journal.pmed.0040066","volume":"4","author":"A Guindo","year":"2007","unstructured":"Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007;4:e66.","journal-title":"PLoS Med"},{"key":"3689_CR22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(02)08273-9","volume":"359","author":"M Aidoo","year":"2002","unstructured":"Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet. 2002;359:1311\u20132.","journal-title":"Lancet"},{"key":"3689_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.mib.2006.06.009","volume":"9","author":"TN Williams","year":"2006","unstructured":"Williams TN. Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006;9:388\u201394.","journal-title":"Curr Opin Microbiol"},{"key":"3689_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0140-6736(67)91037-9","volume":"1","author":"H Gilles","year":"1967","unstructured":"Gilles H, Fletcher K, Hendrickse R. Glucose-6-phosphate-dehydrogenase deficiency, sickling, and malaria in African children in South Western Nigeria. Lancet. 1967;1:138\u201340.","journal-title":"Lancet"},{"key":"3689_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nri1311","volume":"4","author":"MM Stevenson","year":"2004","unstructured":"Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol. 2004;4:169\u201380.","journal-title":"Nat Rev Immunol"},{"key":"3689_CR26","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.4049\/jimmunol.1700807","volume":"199","author":"AA Obajemu","year":"2017","unstructured":"Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, et al. IFN-\u03bb4 attenuates antiviral responses by enhancing negative regulation of IFN signaling. J Immunol. 2017;199:3808\u201320.","journal-title":"J Immunol"},{"key":"3689_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm.3424","volume":"20","author":"P Liehl","year":"2014","unstructured":"Liehl P, Zuzarte-Lu\u00eds V, Chan J, Zillinger T, Baptista F, Carapau D, et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med. 2014;20:47\u201353.","journal-title":"Nat Med"},{"key":"3689_CR28","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1128\/JVI.00272-10","volume":"84","author":"M Mordstein","year":"2010","unstructured":"Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010;84:5670\u20137.","journal-title":"J Virol"},{"key":"3689_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.24.962688","author":"L Prokunina-Olsson","year":"2020","unstructured":"Prokunina-Olsson L, Morrison RL, Obajemu A, Mahamar A, Kim S, Attaher O, et al. IFN-\u03bb4 increases the risk of gastrointestinal infections and malaria in Malian children. BioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.02.24.962688.","journal-title":"BioRxiv."},{"key":"3689_CR30","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1038\/emboj.2013.232","volume":"32","author":"OJ Hamming","year":"2013","unstructured":"Hamming OJ, Terczy\u0144ska-Dyla E, Vieyres G, Dijkman R, J\u00f8rgensen SE, Akhtar H, et al. Interferon lambda 4 signals via the IFN\u03bb receptor to regulate antiviral activity against HCV and coronaviruses: recombinant IFN\u03bb4 is antiviral. EMBO J. 2013;32:3055\u201365.","journal-title":"EMBO J"},{"key":"3689_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/21505594.2020.1768329","volume":"11","author":"WO Hahn","year":"2020","unstructured":"Hahn WO, Pepper M, Liles WC. B cell intrinsic expression of IFN\u03bb receptor suppresses the acute humoral immune response to experimental blood-stage malaria. Virulence. 2020;11:594\u2013606.","journal-title":"Virulence"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03689-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03689-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03689-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:38:26Z","timestamp":1618983506000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03689-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3689"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03689-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-74934\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"8 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and study procedures were approved by the institutional review board of the SUNY Upstate Medical University (where the study was initiated), COMIRB at University of Colorado, and the Scientific and ethical review unit (SERU) at KEMRI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}